CN Patent

CN102133402B — 囊性纤维化跨膜转导调节因子抑制剂在制备治疗糖尿病药物中的应用

Assigned to Beijing Tongren Hospital · Expires 2013-06-12 · 13y expired

What this patent protects

本发明涉及囊性纤维化跨膜转导调节因子抑制剂在制备治疗糖尿病药物中的应用,以及噻唑烷酮化合物或其衍生物在制备治疗糖尿病药物中的应用。该囊性纤维化跨膜转导调节因子抑制剂可以与磺脲类、格列萘类、双胍类、胰岛素增敏剂类、糖苷酶抑制剂类药物配伍使用。

USPTO Abstract

本发明涉及囊性纤维化跨膜转导调节因子抑制剂在制备治疗糖尿病药物中的应用,以及噻唑烷酮化合物或其衍生物在制备治疗糖尿病药物中的应用。该囊性纤维化跨膜转导调节因子抑制剂可以与磺脲类、格列萘类、双胍类、胰岛素增敏剂类、糖苷酶抑制剂类药物配伍使用。

Drugs covered by this patent

Patent Metadata

Patent number
CN102133402B
Jurisdiction
CN
Classification
Expires
2013-06-12
Drug substance claim
No
Drug product claim
No
Assignee
Beijing Tongren Hospital
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.